to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Landing an angel investment takes a special approach. Learn from the advice of those who've tried and succeeded at lining up angel investors for their healthcare businesses.
Pharmaceutical companies are trying to adapt their marketing to an increasingly digital world. To get a handle on this environment, one company has appointed a digital advisory board of marketers from other industries.
Pharma reps at GSK are selling their products in a new way. The emphasis is more on communicating a drug's benefits and risks than trying to sell as much as possible. Read more about this change in approach to sales.
Talk of a possible tech bubble, based on high valuations of IT companies, has led to questions about whether a health IT bubble has been created as well. Read more about the signs leading to that speculation.
Life sciences business owners are seeing a modest rise in venture capital funds – no mean feat in this economy. But one big communications mistake will take you and your firm out of the running.
For medical device startups and biotech companies, a microloan may be what enables them to purchase a new piece of equipment. Read more about a Northeast Ohio microloan fund that recently launched to help small businesses in that area.
At-the-market offerings are used for investing in other industries, but they are just starting to pick up in life science investing. Read more on what the healthcare business should know about ATM offerings.
The largest angel investor groups can be found in Ohio, California and New York. Read more about these medical business resources.
Wouldn’t every healthcare business entrepreneur like to have access to business experts and a connection to investors? These are two components of Minnesota Angel Network’s new program.
Life sciences venture capital investing rose in the second quarter, due in part to increased exit activity. Read more for details on life sciences companies’ deals.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.